Proactive Research analyst Robin Davison presents his research on Poolbeg Pharma (Poolbeg Pharma PLC (AIM:POLB)) after the firm signed an option agreement with University College Dublin for MelioVac.
As Davison explains, this is a late preclinical-stage infectious disease vaccine for Burkholderia pseudomallei, the bacterium that causes the tropical disease melioidosis.
He says the option provides a period of time for Poolbeg to complete its due diligence before signing a formal licensing agreement. The company is also evaluating candidates for five other early-stage infectious disease products from the same team at University College Dublin (UCD).